Publications

Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases

 119
Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases

Tags:

Previous Article

ALS drug effectively treats Alzheimer’s disease

Next Article

Inhibition of ceramide synthesis contributes to cardiometabolic diseases

Related Posts

Regulated TRESLIN-MTBP loading governs initiation zones and replication timing in human DNA replication

Regulated TRESLIN-MTBP loading governs initiation zones...

 81

SLC25A1 and ACLY maintain cytosolic acetyl-CoA and regulate ferroptosis susceptibility via FSP1 acetylation

SLC25A1 and ACLY maintain cytosolic acetyl-CoA and regu...

 98

Cell-type-directed network-correcting combination therapy for Alzheimer’s disease

Cell-type-directed network-correcting combination thera...

 100